OUR APIS FIT YOUR REQUIREMENTS 100%
Arevipharma offers a broad range of synthetic, generic active ingredients in various volume, indication and substance classes. All active ingredients are produced at the site in Radebeul under cGMP conditions and are already registered in many global pharmaceutical markets. In consultation with our customers, we also regularly tackle registration projects in countries that are additionally required for their marketing strategy, at short notice and reliably.
Narcotics represent an important part of our portfolio of active ingredients. Arevipharma can handle all classes of these active ingredients without any restrictions on their volumes. This makes us one of the largest producers of narcotics in the world.
APIs
Controlled Substances
| Product | Indication | Regulatory Documentation |
|---|---|---|
| Amfepramon HCl | Appetite Depressant | US-DMF, ASMF |
| Arketamine HCl* | Antidepressant | ASMF |
| Buprenorphine | Analgesic,OUD | CEP, US-DMF, ASMF |
| Buprenorphine HCl | Analgesic | CEP, US-DMF, ASMF |
| Esketamine HCl* | Analgesic, Antidepressant | CEP, US-DMF, ASMF |
| Fentanyl | Analgesic | CEP, ASMF |
| Fentanyl Citrate | Analgesic | CEP, ASMF |
| Ketamin HCl* | Analgesic | CEP, US-DMF, ASMF |
| Remifentanil Hydrochloride | Analgesic | CEP, ASMF |
| Tilidine HCl | Analgesic | CEP, ASMF |
*not a controlled substance in several countries (e.g. Germany)
Other APIS
| Product | Indication | Regulatory Documentation |
|---|---|---|
| Amiodarone HCl | Antiarrhythmic | CEP, ASMF |
| Bisoprolol Fumarate | Antihypertonic, beta block | CEP, US-DMF, J-DMF, ASMF |
| Cafedrine HCl | Cardiac Stimulant | ASMF |
| Cannabidiol | Anti-epileptic, Various | ASMF |
| Carbamazepine | Antiepileptic, Anticonvulsant | CEP, ASMF |
| Cetirizine 2HCl | Antihistaminic | CEP, ASMF |
| Dimethylfumarate | Psoriasis, Multiple Sclerosis | US-DMF, ASMF |
| Doxapram HCl | Analeptic | CEP, US-DMF, J-DMF |
| Ebastine | Antihistaminic | CEP, ASMF |
| Phenprocoumon | Anticoagulant | ASMF |
| Phytosterol | Urological diseases | ASMF |
| Pyridostigmine Bromide | Parasympathomimetic | CEP, C-DMF, ASMF |
| Sotalol HCl | Antiarrhythmic, Beta blocker | CEP, ASMF |
| Sultiame | Antiepileptic, Anticonvulsant | ASMF |
| Theodrenaline HCl | Cardiac Stimulant | ASMF |
| Torasemide | Diuretic | CEP, ASMF, J-DMF |
R&D PRODUCTS
| Product | Indication | Status |
|---|---|---|
| Alpelsib | Anticancer | Under Evaluation |
| Diroximel Fumarate | Multiple Sclerosis | Under Evaluation |
| Gilteritinib | Anticancer | Under Evaluation |
| (Hydroxy-/)Norketamine | Antidepressant | Laboratory Assessment |
| Nalburphine HCl | Analgesic, partial antagonist | Validation 2025 |
| Nalmefene HCl | Opiod Antagonist | Validation 2025 |
| Naloxone HCl | Opiod Antagonist, Alcohol dependence | Validation 2025 |
| Naltrexone Base | Opiod Antagonist, OUD | Validation 2025 |
| Naltrexone HCl | Opiod Antagonist, OUD | Validation 2025 |
| Oliceridine | Analgesic | Under Evaluation |
| Ribociclib | Anticancer | Under Evaluation |
| Rivastigmine (Tartrate) | Alzheimer’s Disease | Validation Q2 2024 |
| Sufentanil | Analgesic | Laboratory Assessment |
| Tirbanibulin | Actinic keratosis | Under Evaluation |
| Tivozanib | Anticancer | Laboratory Assessment |
| Vismodegib | Anticancer | Laboratory Assessment |